Drug Approval Reforms Ineffective Without Payer Reforms, Tunis Argues
Granting payers more conditional coverage authority may be necessary for legislation to succeed at accelerating biomedical innovation, the former CMS CMO argues, but industry may not be on board.
You may also be interested in...
Congressional budget projections should use longer time horizons, Vice-Chair of House Energy and Commerce Health Subcommittee argues; meanwhile former FDA Commissioner suggests costly drugs could be paid for on a mortgage model.
House Energy and Commerce’s 21st Century Cures Initiative hears arguments for why exclusivity reform is necessary, but Rep. Waxman argues that more research about its impact on drug discovery is needed first.
Republicans dominate first official 21st Century Cures hearing, but Net Neutrality forces many members to choose, and the initiative’s leader makes quick exit.